IL6 and Sepsis: Our work aimed to investigate whether serum IL-6 or leukocyte CPD could be adequate biomarkers for survival prediction and SA-AKI development in immunocompetent and immunocompromised patients with newly diagnosed sepsis admitted to the ICU and, therefore, aid the clinicians’ assessment of sepsis severity.